default author photo

Anna M. Grabowska

Ex Vivo Cancer Pharmacology Centre of Excellence

Nottingham

United Kingdom

  • Ex Vivo Cancer Pharmacology Centre of Excellence

SCHOLARLY PAPERS

1

DOWNLOADS

40

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Modulation of the Tumor Promoting Functions of Cancer Associated Fibroblasts by Phosphodiesterase Type 5 Inhibition Increases the Efficacy of Chemotherapy in Human Preclinical Models of Esophageal Adenocarcinoma

Number of pages: 95 Posted: 15 Sep 2021
Antigoni Manousopoulou, Annette Hayden, Andrew Cowie, Benjamin P. Sharpe, Robert C. Walker, Fereshteh Izadi, Fereshteh Izadi, Stella P. Breininger, Ewan Kyle, John H. Saunders, Simon L. Parsons, Simon L. Parsons, Alison A. Ritchie, Philip A. Clarke, Pamela Collier, Spiros D. Garbis, Zoë Walters, Matthew Rose-Zerilli, Anna M. Grabowska, Timothy J. Underwood and Jack Harrington
Proteas Bioanalytics Inc., University of Southampton - School of Cancer Sciences, University of Southampton - School of Cancer Sciences, University of Southampton - School of Cancer Sciences, University of Southampton - School of Cancer Sciences, Swansea University - Swansea University Medical School, University of Southampton - School of Cancer Sciences, University of Southampton - School of Cancer Sciences, University of Nottingham - Ex Vivo Cancer Pharmacology Centre of Excellence, Nottingham University Hospitals NHS Trust, University of Nottingham - Ex Vivo Cancer Pharmacology Centre of Excellence, University of Nottingham - Ex Vivo Cancer Pharmacology Centre of Excellence, University of Nottingham - Ex Vivo Cancer Pharmacology Centre of Excellence, Proteas Bioanalytics Inc., University of Southampton - School of Cancer Sciences, University of Southampton - School of Cancer Sciences, University of Nottingham - Ex Vivo Cancer Pharmacology Centre of Excellence, University of Southampton - School of Cancer Sciences and University of Southampton - School of Cancer Sciences
Downloads 40

Abstract:

Loading...

esophageal adenocarcinoma, cancer associated fibroblasts, phosphodiesterase type 5 inhibitors, chemotherapy, preclinical models